ASND · Ascendis Pharma A/S
Market Cap
$16.41B
Shares
65.59M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 6-K | 2026-08-13 | 2026-06-30 | |
| 6-K | 2026-08-13 | — | |
| 6-K | 2026-08-12 | — | |
| 6-K | 2026-08-06 | — | |
| 6-K | 2026-07-15 | — | |
| 6-K | 2026-06-30 | — | |
| 6-K | 2026-06-29 | — | |
| 6-K | 2026-06-17 | — | |
| 6-K | 2026-06-15 | — | |
| 6-K | 2026-06-12 | — | |
| 6-K | 2026-06-10 | — | |
| 6-K | 2026-05-13 | — | |
| 6-K | 2026-05-07 | 2026-03-31 | |
| 6-K | 2026-05-07 | — | |
| 6-K | 2026-04-21 | — | |
| 6-K | 2026-04-21 | — | |
| 6-K | 2026-04-20 | — | |
| 6-K | 2026-04-16 | 2026-04-15 | |
| 6-K | 2026-04-08 | — | |
| 6-K | 2026-04-08 | — | |
| 6-K | 2026-04-07 | 2026-04-06 | |
| 6-K | 2026-03-30 | — | |
| 6-K | 2026-03-24 | — | |
| 6-K | 2026-03-17 | — | |
| 6-K | 2026-03-16 | — | |
| 6-K | 2026-03-11 | — | |
| 6-K | 2026-03-02 | 2026-02-28 | |
| 6-K | 2026-02-23 | — | |
| 6-K | 2026-02-11 | 2026-02-10 | |
| 20-F | 2026-02-11 | 2025-12-31 | |
| 6-K | 2026-02-11 | — | |
| 6-K | 2026-01-14 | — | |
| 6-K | 2026-01-12 | — | |
| 6-K | 2026-01-09 | 2026-01-08 | |
| 6-K | 2025-12-30 | — | |
| 6-K | 2025-12-10 | — | |
| 6-K | 2025-11-26 | 2025-11-25 | |
| 6-K | 2025-11-12 | — | |
| 6-K | 2025-11-12 | 2025-09-30 | |
| 6-K | 2025-11-12 | — | |
| 6-K | 2025-10-22 | — | |
| 6-K | 2025-10-15 | — | |
| 6-K | 2025-10-08 | — | |
| 6-K | 2025-09-30 | — | |
| 6-K | 2025-09-10 | — | |
| 6-K | 2025-08-13 | — | |
| 6-K | 2025-08-07 | 2025-06-30 | |
| 6-K | 2025-08-07 | — | |
| 6-K | 2025-07-28 | — | |
| 6-K | 2025-07-09 | — |
Showing 1–50 of 288 filings
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
269 filings
266 filers
Visit website
Investor relations